Identifying biomarkers for radiation sensitivity in cancer patients
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
This study is trying to find out if certain blood and tissue markers can help predict how sensitive cancer patients are to radiation therapy, especially those who have had bad side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Singapore) |
| Trial ID | NCT04340024 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit patients with nasopharyngeal cancer, prostate cancer, or other cancers that are sensitive to radiotherapy, particularly those who have experienced severe side effects from such treatments. Blood and matched tumor-normal tissue samples will be collected from participants to analyze genetic and biochemical markers. The goal is to identify biomarkers that could predict individual sensitivity to radiation therapy, enhancing personalized treatment approaches in oncology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 21 to 98 who have experienced severe side effects from radiotherapy or have cancers known to be sensitive to radiation.
Not a fit: Patients outside the age range of 21 to 98 or those without severe side effects from radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to more tailored radiotherapy treatments, minimizing side effects and improving outcomes for cancer patients.
How similar studies have performed: While the approach of identifying biomarkers for radiation sensitivity is being explored in various contexts, this specific study focuses on a novel combination of genomics and immunomics in the context of radiotherapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with severe side effects from radiotherapy * Patients with a type of cancer that is associated with sensitivity to radiotherapy Exclusion Criteria: * Age of patient must be between 21 (inclusive) and 99 (exclusive)
Where this trial is running
Singapore
- National Cancer Center Singapore — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Melvin Chua, MD — National Cancer Centre, Singapore
- Study coordinator: Melvin Chua, MD
- Email: melvin.chua.l.k@singhealth.com.sg
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.